Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study - Thaçi, Diamant (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Reich, Kristian (Dermatologikum Berlin and SCIderm Research Institute) ; Tsai, T. F. (National Taiwan University Hospital (Taipei, Taiwan)) ; Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ; Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ; Ziv, M. (Emek Medical Center) ; Pinter, A. (Department of Dermatology. University of Frankfurt) ; Vender, Ronald (Venderm Innovations in Psoriasis) ; Lacombe, A. (Novartis Pharma AG) ; Xia, Shang (Novartis Beijing Novartis Pharma Co Ltd) ; Bhosekar, V. (Novartis Healthcare Pvt Ltd) ; Gilloteau, I. (Novartis Pharma AG) ; Guana, Adriana (Novartis Pharmaceuticals Corporation) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Universitat Autònoma de Barcelona